Table 2.
Clinical concordance and risk stratification between the WB GEM® Premier™ ChemSTAT and the plasma Atellica® CH eGFR.
| Number of Patients (%) | ||
|---|---|---|
| Zone a | 30 mL/min/1.73 m2 b | 45 mL/min/1.73 m2 c |
| Zone A: Correct risk classification—appropriate management. | 114 (89.1%) | 114 (89.1%) |
| Zone B: Incorrectly classified, but no implication for clinical management. | 14 (10.9%) | 11 (8.6%) |
| Zone C: Incorrect classification, potential for unnecessary prophylaxis, or withholding of contrast. | 0 (0%) | 3 (2.3%) |
| Zone D: Incorrect classification and potential for increased risk of CIN owing to insufficient prophylaxis. | 0 (0%) | 0 (0%) |
a Performance zones for risk categorization based on the CKD-EPI eGFR calculations, as defined by Snaith et al. [6]. b Renal-risk cut-off of eGFR < 30 mL/min/1.73 m2. Preventive measures are recommended before intravenous and intra-arterial CM administration, with second-pass renal exposure [9,10]. c Renal-risk cut-off of eGFR < 45 mL/min/1.73 m2. Preventive measures are recommended before intra-arterial CM administration, with first-pass renal exposure, and for intensive care unit patients [9,10].